Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott heart drugs reveal mixed results

Abbott heart drugs reveal mixed results

15th November 2005

Research into experimental heart disease drugs from Abbott Laboratories has given contradictory results.

Results from studies into the drugs Simdex and TriCor were presented at the annual scientific meeting of the American Heart Association (AHA). Researchers found that the former drug increased the chance of improvement and lessened worsening in patients, although some showed concern of an increased number of deaths with those taking Simdex.

But research into TriCor, which is designed for Type 2 diabetics, found that the drug failed to reduce the number of deaths and heart attacks in patients. But the drug succeeded in reducing bleeding in the eyes and the need for surgery.

In a statement, Abbott Laboratories said that it had conducted the study to find better ways of treating heart disease in diabetics. “The FIELD study was conducted to determine whether early intervention with fenofibrate could prevent cardiovascular events in patients with type 2 diabetes,” it said.

The lead research of the TriCor study, also known as FIELD, associate professor of medicine Dr Anthony Keech, told Reuters: “Clearly, the results of the trial were mixed.”

But even Simdex was not free from criticism. JP Morgan analyst Michael Weinstein told the agency that “the underlying side effect and mortality profile” of Simdex, despite its positive results, “raises a number of concerns and may put the drug’s future in jeopardy.”

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.